EUCTR2006-001897-26-NL进行中（未招募）不适用
A Phase 2 Multicenter Study of CNTO 328 (Anti Interleukin 6 Monoclonal Antibody) in Subjects with Relapsed or Refractory Multiple Myeloma - C0328T05 in relapsed/refractory MM patients
Centocor B.V.0 个研究点目标入组 40 人开始时间: 2006年7月5日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be eligible for the study, subjects must meet all of the following criteria:
- •1. Male or female age = 18 years
- •2. Signed informed consent obtained prior to any study-specific screening procedures
- •3. Genetic testing Subjects must have signed the informed consent for genetic testing indicating whether they do or do not wish to participate in the genetic part of the study. Participation in the genetic testing component is not mandatory for participation in the study
- •4. Confirmed diagnosis of multiple myeloma
- •5. Relapsed or refractory disease defined as:
- •a. Failed at least 2 prior lines of therapy
- •b. Documented relapse after completion of last treatment or no response to last prior therapy. Progression on prior therapy is defined according to EBMT criteria.
- •c. Other acceptable prior lines of therapy include: High-dose corticosteroids, autologous stem cell transplant (high-dose corticosteroids followed by autologous stem cell transplant are considered 1 line of therapy), lenalinomide/thalidomide (alone or in combination with other agents), anthracycline and/or alkalylating agent (melphalan) (alone or in combination with other agents), and bortezomib (alone or in combination with other agents)
- •6. Prior treatment regimen must have included bortezomib (alone or in combination with other agents)
- •7. Measurable secretory disease defined as either serum monoclonal paraprotein (M protein) = 1 g/dL or urine monoclonal (light chain) protein (> 200 mg/24 hours)
- •8. Eastern Cooperative Oncology Group (ECOG) performance status score of = 2
- •9. Subjects experiencing toxicities resulting from previous therapy must have fully recovered or stabilized to = Grade 1
- •10. Subjects of childbearing potential must use adequate birth control measures. Female subjects of childbearing potential must have a negative serum pregnancy test at screening
- •11. Adequate bone marrow, liver, and renal function prior to treatment:
- •a. Hemoglobin = 7.5 g/dL (4.7 mmol/L; 75 g/L) with or without transfusion dependency
- •b. Platelets = 50,000/mm3 without transfusion dependency.
- •c. Absolute neutrophil count (ANC) = 1000 mm3 without hematopoietic cytokine support
- •d. AST, ALT, and alkaline phosphatase = 3 x ULN
- •e. Bilirubin = 2 x ULN
- •f. Calculated creatinine clearance = 20 mL/min
- •g. Corrected serum calcium = 11.5 mg/dL (2.8 mmol/L)
- •12. Able to adhere to study visit schedule and all protocol requirements
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects meeting any of the following criteria may not be enrolled in the study:
- •1. Treatment with systemic cancer therapy (including clarithromycin) or radiotherapy within 30 days before the first dose of study agent
- •2. Treatment with nitrosoureas within 42 days before the first dose of study agent
- •3. Major surgery within 30 days before the first dose of study agent or planning to have surgery (except for minor surgical procedures) during the study
- •4. Received any investigational drug/agent within 30 days or 5 half-lives, whichever is longer
- •5. Received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant
- •6. Has clinically significant residual toxicities associated with prior autologous bone marrow or peripheral blood stem cell transplant
- •7. Administered platelet transfusion or neutrophil growth factor within 2 weeks prior to the collection of screening hematology laboratory sample
- •8. Transplanted solid organ with the exception of a corneal transplant (= 3 months prior to screening)
- •9. Received any mAb within 60 days of first dose of study agent
- •10. Serious concurrent illness (medical or psychiatric), uncontrolled infection, or significant cardiac disease characterized by significant ischemic coronary disease or congestive heart failure not under medical control, or any uncontrolled medical condition (eg, uncontrolled diabetes), including the presence of clinical laboratory abnormalities, that places the subject at unacceptable risk by participating in the study or confounds the ability to interpret data from the study
- •11. Prior or concomitant malignancy (other than multiple myeloma) except adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or other cancer for which the subject has been disease-free for = 3 years
- •12. Any other concomitant disease-related treatment such as, immunotherapy, biotherapy, radiotherapy, chemotherapy, investigative therapy, or immunosuppressive therapy/corticoid steroids (other than study specific treatment with dexamethasone)
- •13. Vaccinated with live or attenuated vaccines within 4 weeks of the first administration of CNTO 328
- •14. Known to be seropositive for HIV, or active hepatitis A, B or C infection
- •15. Pregnant or lactating women
研究者
相似试验
进行中（未招募）
1 期
A Phase II Study of Intravenous CNTO328 in Patients with Recurrent Epithelial Ovarian Cancer - CNTO328 in ovarian cancerEUCTR2006-005704-13-GBQueen Mary, University of London
进行中（未招募）
不适用
A Phase 2 Multicenter, Open-label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination with Mitoxantrone versus Mitoxantrone in Subjects with Metastatic Hormone-Refractory Prostate Cancer (HRPC)Metastatic Hormone-Refractory Prostate Cancer (HRPC)MedDRA version: 8.1Level: LLTClassification code 10062904Term: Hormone-refractory prostate cancerEUCTR2006-001671-38-DECentocor B.V.134
进行中（未招募）
不适用
A Phase 2 Multicenter, Open-label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination with Mitoxantrone versus Mitoxantrone in Subjects with Metastatic Hormone-Refractory Prostate Cancer (HRPC)EUCTR2006-001671-38-ATCentocor B.V.134
进行中（未招募）
不适用
A Phase 2 Multicenter, Open-label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination with Mitoxantrone versus Mitoxantrone in Subjects with Metastatic Hormone-Refractory Prostate Cancer (HRPC)Metastatic Hormone-Refractory Prostate Cancer (HRPC)MedDRA version: 8.1Level: LLTClassification code 10062904Term: Hormone-refractory prostate cancerEUCTR2006-001671-38-BECentocor B.V.134
进行中（未招募）
1 期
A Phase 2 Multicenter, Open-label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination with Mitoxantrone versus Mitoxantrone in Subjects with Metastatic Hormone-Refractory Prostate Cancer (HRPC)EUCTR2006-001671-38-FRCentocor B.V.